D
Deborah Forst
Researcher at Harvard University
Publications - 39
Citations - 837
Deborah Forst is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 6, co-authored 23 publications receiving 429 citations. Previous affiliations of Deborah Forst include Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells
Philipp Karschnia,Philipp Karschnia,Justin T. Jordan,Deborah Forst,Isabel Arrillaga-Romany,Tracy T. Batchelor,Joachim M. Baehring,Nathan F. Clement,L. Nicolas Gonzalez Castro,Aline Herlopian,Marcela V. Maus,Michaela H. Schwaiblmair,Jacob D. Soumerai,Ronald W. Takvorian,Ephraim P. Hochberg,Jeffrey A. Barnes,Jeremy S. Abramson,Matthew J. Frigault,Jorg Dietrich +18 more
TL;DR: It was found that lower platelet counts at time of CAR T-cell infusion were associated with more severe neurotoxicity, and high pretreatment lactate dehydrogenase was frequently encountered in lymphoma patients with grade 3-4 neurotoxicity and correlated negatively with progression-free survival.
Journal ArticleDOI
Low-Grade Gliomas
TL;DR: Current management strategies for LGG are reviewed, including surgery, radiotherapy, and chemotherapy, and the importance of profiling the genetic and molecular properties of LGGs in the development of targeted anticancer therapies is also reviewed.
Journal ArticleDOI
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis
Benjamin Kasenda,Andrés José Maria Ferreri,E. Marturano,Deborah Forst,Jacoline E C Bromberg,Herve Ghesquieres,Celine Ferlay,Jean-Yves Blay,Khê Hoang-Xuan,Elisa Jacobsen Pulczynski,Alexander Fosså,Yasushi Okoshi,Shigeru Chiba,Kristina Fritsch,Antonio Omuro,Brian P. O'Neill,Osnat Bairey,Osnat Bairey,Stefan Schandelmaier,Viktoria Gloy,Neera Bhatnagar,S. Haug,S. Rahner,Tracy T. Batchelor,Gerald Illerhaus,Matthias Briel,Matthias Briel +26 more
TL;DR: Elderly PCNSL patients benefit from HD-MTX-based therapy, especially if combined with oral alkylating agents, and more aggressive HD- MTX protocols do not seem to improve outcome.
Journal ArticleDOI
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
Priscilla K. Brastianos,Eudocia Q. Lee,Justine V. Cohen,Sara M. Tolaney,Nan Lin,Nancy Wang,Ugonma Chukwueke,Michael White,Naema Nayyar,Albert H. Kim,Christopher Alvarez-Breckenridge,Ian E. Krop,Maura Mahar,Mia Bertalan,Brian A. Shaw,Joana L. Mora,Nathaniel Goss,Megha Subramanian,Lakshmi Nayak,Jorg Dietrich,Deborah Forst,Brian V. Nahed,Tracy T. Batchelor,Helen A. Shih,Elizabeth R. Gerstner,Beverly Moy,Donald P. Lawrence,Anita Giobbie-Hurder,Scott L. Carter,Kevin S. Oh,Daniel P. Cahill,Ryan J. Sullivan +31 more
TL;DR: Pembrolizumab is safe and feasible and displays promising activity in patients with LMD, and anti-PD-1 monotherapy was safe and associated with a 3-month overall survival of 60%.
Journal ArticleDOI
Safety and Efficacy of Tisagenlecleucel in Primary CNS Lymphoma: A phase I/II clinical trial.
Matthew J. Frigault,Jorg Dietrich,Kathleen Gallagher,Mark Roschewski,Justin T. Jordan,Deborah Forst,Scott R. Plotkin,Daniella Cook,Keagan Casey,Kevin A Lindell,Gabriel D DePinho,K. Katsis,Eva L. Elder,Mark B. Leick,Bryan D. Choi,Nora Horick,Fredric I. Preffer,Meredith Saylor,Steven L. McAfee,Paul O'Donnell,Thomas R. Spitzer,Bimalangshu R. Dey,Zachariah DeFilipp,Areej El-Jawahri,Tracy T. Batchelor,Marcela V. Maus,Yi-Bin Chen +26 more
TL;DR: Tisagenleclecleucel was well tolerated and resulted in a sustained remission in 3/7 (42.9%) of initial responders and 5/12 (41.6%) patients experienced grade 3 ICANS as mentioned in this paper .